Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)
Lexeo Therapeutics (LXEO) posted Preferred Stock Liabilities of $85.3 million for Q3 2023, down 53.92% sequentially from $185.0 million in Q2 2023, and down 53.92% YoY from $185.0 million in Q3 2022.
Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Lexeo Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $85.3 million in Q3 2023.
- Quarterly Preferred Stock Liabilities fell 53.92% year-over-year to $85.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $85.3 million (down 53.92% YoY) and the FY2022 annual result came in at $185.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities fell to $85.3 million in Q3 2023 per LXEO's latest filing, from $185.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $185.0 million in Q3 2022 and troughed at $85.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 85.27 Mn |
| Jun 30, 2023 | 185.03 Mn |
| Mar 31, 2023 | 185.03 Mn |
| Dec 31, 2022 | 185.03 Mn |
| Sep 30, 2022 | 185.03 Mn |